An observational study in Acute Lymphoblastic Leukemia ALL, sponsored by Children's Hospital of Orange County. Recruiting at 1 site in United States. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Children's Hospital of Orange County · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 171 open to participants now, 277 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.
Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 123rd largest by planned enrollment of the 154 observational ones that give a count, is one of 39 that started in 2026, is one of 155 observational ones, reaches primary completion later than 149 of the 275 other live ones, and was the 1,543rd registered.
2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →171 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18+
St. Jude Children's Research Hospital · Sites in United States
Ages 8–18 · Healthy volunteers
National Cancer Institute (NCI) · Sites in United States
Ages 1–25
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 0 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,545 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 653 · Phase 2 593 · Phase 3 107 · Phase 4 10
First in 1984; this study’s year is marked. 39 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 108 across 400 observational studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 35 across the 1,269 interventional studies, 110 across the 154 observational. Of the 1,180 that completed or were terminated, 437 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
213 of 1,545 have an industry lead sponsor. The 10 most frequent:
Children's Hospital of Orange County is the lead sponsor of 19 studies on the registry; 11 are open to participants now.
Children's Hospital of Orange County has 2 studies filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
96 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03020030Phase 3Dana-Farber Cancer InstituteTreatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | 2026-11-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04851717Phase 3Acacia Pharma LtdInvestigation of Remimazolam in Children Undergoing Sedation for Medical Procedures | 2027-10 |
| NCT03104491Leland MethenyInotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | 2026-11 |
| NCT06795126Nationwide Children's HospitalLittle NIRVANA for Pediatric Pain and Anxiety | 2026-11-30 |
Add all 96 to your calendar (.ics) → With an account.
Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Brief Summary The purpose of this observational study is to better understand how vitamin D levels affect the gut microbiome (the bacteria that live in the intestines) in children who are newly diagnosed with acute lymphoblastic leukemia (ALL). Researchers want to learn whether low vitamin D levels are linked to changes in gut bacteria and whether this may affect how children with ALL respond to chemotherapy.
The main questions this study aims to answer are:
The results of this study may help doctors understand whether monitoring and managing vitamin D levels could improve care and treatment outcomes for children with ALL.
Participants will:
Have four study visits:
Detailed description:
This pilot observational study will evaluate how vitamin D (VitD) levels are related to the gut microbiome in children newly diagnosed with acute lymphoblastic leukemia (ALL), and how these relationships change during early chemotherapy treatment.
Aim 1:
To determine whether vitamin D status affects the gut microbiome at the time of ALL diagnosis. The study hypothesizes that children with vitamin D deficiency will have lower gut microbiome diversity and different microbial and metabolomic profiles compared to children with sufficient vitamin D levels.
A baseline stool sample will be collected within ±4 days of starting induction therapy, prior to significant chemotherapy exposure. Samples will be processed and stored at -80°C and analyzed using metagenomic sequencing and untargeted metabolomics to evaluate microbial composition, diversity, and metabolic pathways. Baseline vitamin D levels (25-hydroxyvitamin D [25(OH)D]) and relevant clinical data will be obtained.
Aim 2:
To determine whether maintaining sufficient vitamin D levels during treatment supports gut microbiome diversity and function. As part of standard clinical care, patients with 25(OH)D levels \<30 ng/mL will receive vitamin D supplementation managed by the oncology team.
Follow-up stool samples will be collected:
Targeted metabolomic analysis will be performed in patients with persistent vitamin D deficiency despite supplementation to explore whether gut microbiota influence vitamin D metabolism. The study will also assess changes in microbiome diversity over time within individuals using a paired design to reduce variability.
Exploratory Outcomes:
Clinical outcomes will be retrospectively collected from medical records to explore associations between gut microbiome diversity and treatment-related outcomes, including:
Significance:
This study will provide foundational data on the interaction between vitamin D status and the gut microbiome in pediatric ALL. Results may inform future strategies to monitor and optimize vitamin D levels to preserve gut microbial health and potentially improve treatment outcomes in pediatric oncology patients.
Oncology unit at Children's Hospital of Orange County
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gut microbiome diversity
Bacterial 16S ribosomal RNA gene targeted sequencing will be performed using the Quick-16S™ NGS Library Prep Kit (Zymo Research, Irvine, CA). Bioinformatic analysis includes Absolute Abundance, Composition barplots, Taxonomy Heatmaps, Alpha and Beta Diversity, and LEfSe Analysis.
Time frame: Through study completion, up to 97 days
Baseline 25[OH]D levels
Clinical outcomes will be collected retrospectively from patients' electronic medical records, including baseline 25(OH)D levels at the time of cancer diagnosis.
Time frame: Baseline
MRD levels at the end of induction chemotherapy
Clinical outcomes will be collected retrospectively from patients' electronic medical records, including MRD levels at the end of induction chemotherapy (EOI, Day 29).
Time frame: At the end of induction chemotherapy (Day 29)
Number of ICU admissions
Clinical outcomes will be collected retrospectively from patients' electronic medical records, including the number of ICU admissions, over the study period (up to 97 days).
Time frame: Through study completion (up to 97 days)
Number of infection events
Clinical outcomes will be collected retrospectively from patients' electronic medical records, including infection events confirmed by blood culture or PCR assay, over the study period (up to 97 days).
Time frame: Through study completion, up to 97 days
Length of hospital stay
Clinical outcomes will be collected retrospectively from patients' electronic medical records, including length of hospital stay, over the study period (up to 97 days).
Time frame: Through study completion, up to 97 days
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.
Of 145 non-industry observational studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 143. This study's planned 9 months is below that.
Counting every sponsor, half of 163 studies reached it within 54 months; a quarter within 24 and three quarters within 142.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Children's Hospital of Orange County